Cargando…

Cyclosporine is a potential curative treatment option for advanced thymoma

BACKGROUND: Thymectomy can effectively cure most thymoma patients; however, patients with advanced thymoma typically require chemotherapy, which is associated with limited efficacy in this context. Here we provide the first report of a patient with recurrent thymoma who achieved complete remission (...

Descripción completa

Detalles Bibliográficos
Autores principales: Isshiki, Yusuke, Tanaka, Hiroaki, Suzuki, Yoshio, Yoshida, Yukihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5415741/
https://www.ncbi.nlm.nih.gov/pubmed/28473943
http://dx.doi.org/10.1186/s40164-017-0073-6
_version_ 1783233581892501504
author Isshiki, Yusuke
Tanaka, Hiroaki
Suzuki, Yoshio
Yoshida, Yukihiro
author_facet Isshiki, Yusuke
Tanaka, Hiroaki
Suzuki, Yoshio
Yoshida, Yukihiro
author_sort Isshiki, Yusuke
collection PubMed
description BACKGROUND: Thymectomy can effectively cure most thymoma patients; however, patients with advanced thymoma typically require chemotherapy, which is associated with limited efficacy in this context. Here we provide the first report of a patient with recurrent thymoma who achieved complete remission (CR) using cyclosporine therapy. CASE PRESENTATION: A 63-year-old woman who had undergone resection surgery for recurrent type B1 thymoma developed pure red cell aplasia (PRCA), and CT findings revealed thymoma recurrence. After the initiation of orally-administered cyclosporine, PRCA quickly resolved, and the thymoma disappeared without the administration of any anti-thymoma therapy. The patient has remained in CR for over 3 years using only cyclosporine. CONCLUSIONS: This is the first report describing the curative potential of cyclosporine for the treatment of advanced thymoma. Although the mechanism underlying this effect remains unclear, cyclosporine can become a less toxic and more cost-effective treatment option for thymoma compared with conventional therapy. Clinical trials are needed to confirm the therapeutic potential of cyclosporine as a new treatment option for thymoma.
format Online
Article
Text
id pubmed-5415741
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-54157412017-05-04 Cyclosporine is a potential curative treatment option for advanced thymoma Isshiki, Yusuke Tanaka, Hiroaki Suzuki, Yoshio Yoshida, Yukihiro Exp Hematol Oncol Case Report BACKGROUND: Thymectomy can effectively cure most thymoma patients; however, patients with advanced thymoma typically require chemotherapy, which is associated with limited efficacy in this context. Here we provide the first report of a patient with recurrent thymoma who achieved complete remission (CR) using cyclosporine therapy. CASE PRESENTATION: A 63-year-old woman who had undergone resection surgery for recurrent type B1 thymoma developed pure red cell aplasia (PRCA), and CT findings revealed thymoma recurrence. After the initiation of orally-administered cyclosporine, PRCA quickly resolved, and the thymoma disappeared without the administration of any anti-thymoma therapy. The patient has remained in CR for over 3 years using only cyclosporine. CONCLUSIONS: This is the first report describing the curative potential of cyclosporine for the treatment of advanced thymoma. Although the mechanism underlying this effect remains unclear, cyclosporine can become a less toxic and more cost-effective treatment option for thymoma compared with conventional therapy. Clinical trials are needed to confirm the therapeutic potential of cyclosporine as a new treatment option for thymoma. BioMed Central 2017-05-03 /pmc/articles/PMC5415741/ /pubmed/28473943 http://dx.doi.org/10.1186/s40164-017-0073-6 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Case Report
Isshiki, Yusuke
Tanaka, Hiroaki
Suzuki, Yoshio
Yoshida, Yukihiro
Cyclosporine is a potential curative treatment option for advanced thymoma
title Cyclosporine is a potential curative treatment option for advanced thymoma
title_full Cyclosporine is a potential curative treatment option for advanced thymoma
title_fullStr Cyclosporine is a potential curative treatment option for advanced thymoma
title_full_unstemmed Cyclosporine is a potential curative treatment option for advanced thymoma
title_short Cyclosporine is a potential curative treatment option for advanced thymoma
title_sort cyclosporine is a potential curative treatment option for advanced thymoma
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5415741/
https://www.ncbi.nlm.nih.gov/pubmed/28473943
http://dx.doi.org/10.1186/s40164-017-0073-6
work_keys_str_mv AT isshikiyusuke cyclosporineisapotentialcurativetreatmentoptionforadvancedthymoma
AT tanakahiroaki cyclosporineisapotentialcurativetreatmentoptionforadvancedthymoma
AT suzukiyoshio cyclosporineisapotentialcurativetreatmentoptionforadvancedthymoma
AT yoshidayukihiro cyclosporineisapotentialcurativetreatmentoptionforadvancedthymoma